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OPTIMIZATION OF VIRAL TRANSDUCTION IN CENTRAL NERVOUS 
SYSTEM  
 
DANIEL ROBERT BURT 
 
ABSTRACT 
 
 Genetically based Central Nervous System (CNS) disorders remain a largely 
unresolved issue in the world today. Our genome is the source of our greatest strengths 
and weaknesses. For this reason, intelligent modification of the genome’s DNA is a 
profoundly beneficial goal in the maximization of the overall health of the human race. 
Potential benefit in this field is currently limited in both effectiveness and safety in 
regards to the delivery of therapeutic genes into the nucleus, which is protected by many 
evolution-based barriers. Evolution has also favored the development of highly 
specialized and infectiously effective viruses capable of overcoming such boundaries.  
By neutering the naturally occurring and pathologically benign Adeno-Associated Virus 
(AAV) we have transformed what was once a virus, into a “pure” vector, taking full 
advantage of evolution’s diligent enhancement of these genetic hijackers without 
introducing unacceptable danger to patients.  
 We utilized the logically engineered, castrated form of AAV serotype 9 
(recombinant AAV9/rAAV9) to act as a vehicle for two reporter genes, Enhanced Green 
Fluorescent Protein  (EGFP) and Firefly Luciferase (Fluc) with the goal of assessing and 
	  	   vii 
improving the efficiency of vector transduction in murine CNS. We found that rAAV9, 
when infused into the intrathecal space of mice is capable of extensive and intensive 
transduction of both neurons and astrocytes throughout the entire length of the SC as well 
as the hind regions of the brain (brainstem and cerebellum). We also found that efficiency 
of transduction was best in our highest dose groups, 1E+12 genome copies (GC) in 
Experiment 1 and 2E+12 GC in Experiment 2, both of which received rAAV9 particles 
via the two commercially available (100μL and the 200μL) ALZET® Osmotic Pump 
designs. Administering dosage higher than this directly into the intrathecal space was 
limited by the size of the pump reservoir and rAAV9 production titer. We are currently 
attempting to achieve a more complete CNS transduction by performing another 
experiment in which we place the pump cannula directly into the intracerebroventricular  
(ICV) space of the lateral ventricles.  
Our findings reveal that infusion of rAAV9 by intrathecal placed pump cannula is 
more effective than any other method tested in this study int the transduction of neurons 
and glial cells of adult-mouse CNS. By elucidating a mode of delivery that maximizes the 
robustness of transduction efficiency, our results are a critical building block in designing 
a cure for the array of genetic-based diseases of the CNS, which are currently untreatable. 
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INTRODUCTION 	  
General Review of the Mammalian Central Nervous System 
 
 The central nervous system (CNS) is composed of the brain and the spinal cord 
(SC). Its function is to process and integrate information attained from a diverse range of 
sensory receptors throughout the body and to initiate the appropriate response in target 
tissues via efferent output to muscles and glands, or by the direct release of hormones 
into the blood stream.  The importance in the CNS is reflected by its extraordinary 
metabolic needs. The adult human brain constitutes only 2% of the body’s total weight 
however contributes to nearly 20% of the resting metabolic rate [1], receiving roughly 
15% of cardiac output (750 mL/min) [2]. 
 Blood reaches the brain via two pairs of arteries that rise through the neck. The 
right and left internal carotid arteries comprise the first of these two pairs, carrying 
roughly 80% (78% during exercise) of the brain’s blood flow. This blood is primarily 
distributed to the front and middle regions of the cortex and subcortical regions such as 
the basal ganglia [3]. The remaining 20% (22% during exercise) of the brain’s blood 
supply is delivered via the left and right vertebral arteries. These arteries lie deep in the 
neck and run upwards along the vertebral column, anastomosing to form the basilar artery 
near the ventral surface of the pons. Their delivery primarily supplies the posterior cortex 
cerebellum and brain stem [4]. The blood from both the carotid and vertebral arteries mix 
with one another via the posterior communicating arteries, forming a structure known as 
the Circle of Willis located on the basal surface of the hypothalamus. This structure 
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supplies regions of the cortex and deep brain structures (basal ganglia, thalamus, and 
internal capsule) with collateral circulation. Variations in this vascular network are 
common [5]. 
Blood courses to the spinal cord via the anterior spinal artery and the two 
posterior spinal arteries. These three arteries all diverge from the vertebral arteries near 
the location where they join one another to form the basilar artery. They travel caudally 
within the vertebral column along the anterior and dorsal surfaces of the spinal cord 
respectively. An adequate stream of blood is maintained in these vessels over the entire 
length of the SC by the continuous bolstering of collateral blood supply from the 10 to 12 
medullary arteries, which branch off of the dorsal aspect of the aorta. These vessels 
penetrate the vertebral column through the intervertebral foramina [6]. The anterior spinal 
artery provides approximately 75% of the SC’s blood supply and primarily feeds it’s 
anterior region. Occlusion of this vessel is more closely associated with motor deficit 
whereas occlusion of the dorsal arteries is accompanied with sensory deficit [7]. 
 
Cell Types in the Central Nervous System as Targets of Gene Therapy 
 
Of central importance to the functionality of the CNS, neurons play a critical role in 
communication and information storage and retrieval. There are roughly 86 billion 
neurons in the brain [8] and nearly a billion in the spinal cord, which together form an 
estimated 100 trillion synapses [9]. The importance of structure on the function of 
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neurons in the CNS requires that these cells be long-lived. Due to this characteristic of 
neurons, damage and/or loss can be devastating to the organism as a whole. 
Neural regeneration is an attractive topic in scientific literature. Peripheral nerves 
are capable of re-growing axons as long as two conditions are met; the neuronal body 
must remain intact and the distal end of the axon attached to the neuronal body must 
remain encased in the endoneurium. The endoneurium is used as a template for the nerve 
fiber to grow into and also supplies a medium in which Schwann cells can provide a 
constant supply of neural growth factors to the growing appendage. In humans, axonal 
growth rates in the periphery can reach 2 mm/day in small nerves and 5 mm/day in large 
nerves [10]. Neural regeneration in the CNS is limited by many factors, including the 
absence of supportive Schwann cells, however, it has been demonstrated that 
neurogenesis can sometimes occur in many regions of the adult vertebrate brain, and that 
in some regions, such as the subventricular zone and the dentate gyrus of the 
hippocampus, regeneration and proliferation of neuron occurs regularly.  It has been 
shown that this regeneration can be enhanced by genetic modification; such as by 
knocking out the RTN4 gene in mice which codes for the trans-membranous protein 
Neurite Outgrowth Inhibitor (Nogo) [11]. 
In addition to neurons, the CNS is composed of several types of neuroglia (NG) 
(AKA glial cells). NG are essentially support cells of the CNS. Traditionally, they are 
collectively considered to have four primary functions; (1) structural support of the CNS 
tissue, (2) maintenance of ideal conditions for neuronal health (nutrient and oxygen 
delivery and toxin removal), (3) axonal insulation and (4) the destruction of pathogens 
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and pathogenic substances [12]. The total abundance of NG differs between regions of 
CNS and there is also a great deal of variation between species. The ratio of NG: neuron 
also varies in different brain regions [13] and species [14]. The human NG: neuron ratio 
is often erroneously cited as being approximately 10:1 [15]. A more accurate 
measurement is approximately 1: 1 overall, with ratios being roughly 11: 1 in brainstem, 
4:1 in the cortex, and 1: 4 in cerebellum [8].  (Figure 1) 
 
 
FIGURE 1: Quantification of Neuronal and Glial Cell Populations in Different 
Brain Regions 
(Note: Figure 1 is from Azevedo, F.A., et al., Equal numbers of neuronal and nonneuronal cells 
make the human brain an isometrically scaled-up primate brain; cited as reference 8 in this 
thesis) 
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Neuroglia are divided into two general populations; microglia and macroglia.  
This distinction is based on embryologic origin. Microglia are embryological derivatives 
of hematopoietic stem cell precursors that originate exclusively from the extra-embryonic 
yolk sac [16] and migrate (around week 3 of gestation in humans) [17] to the CNS. 
Macroglia are derived from the same precursors as neurons; neural stem cells [18], which 
arise from the neuroectoderm and are the “resident” stem cells of the CNS.  The 
macroglia of the adult CNS are further divided into astrocytes, oligodendrocytes, 
ependymal cells and radial glia. 
Astrocytes, also known as astroglia, are named after their “star-like” morphology. 
They form the scaffolding of the CNS, arranging themselves so that they come into 
contact with their neighboring astrocytes, but have little to no overlap; essentially 
parceling the CNS into territories that are referred to as astrocytic micro-domains. 
Astrocytes communicate with one another via “calcium waves” which pass through gap 
junctions, interconnecting the cytoplasm of adjacent astrocytes. A primary function of 
astrocytes is the regulation of concentrations of the many solutes of the extracellular 
space, most notably glucose, lactate, K+, GABA and glutamate, in order to maintain a 
consistent supply of energy and a stable environment for their neighboring neurons [19]. 
Each astrocyte has many primary processes, each with significant secondary and 
tertiary branching. These appendages are highly modifiable and are strategically 
positioned to encapsulate the capillaries and neuronal synapses within their personal 
micro-domain [20]. Their encapsulation of capillaries forms a structure known as the glia 
limitans, an immunological barrier separating the immune-privileged inner parenchyma 
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of the CNS with the outer components of the brain (pia/ sub-arachnoid/ dura) which are 
exposed to compliment protein and antibodies [21]. The encapsulation of synapses forms 
what is known as “tripartite synapses” [22] allowing for gliotransmission (the direct 
modification of neuronal communication via the uptake and, to some extent, release of 
neurotransmitters such as glutamate, D serine, GABA, ATP etc. [23]). 
 Oligodendrocytes are responsible for the encasing the axons of the CNS with 
myelin sheaths and also contribute to several components of the extracellular matrix. 
Oligodendrocytes have a high metabolic rate and consume glucose and lactate to a great 
extent than even neurons, mostly because of the energy requirements for the production 
of myelin [24]. Temporary deficiency of energy in the CNS can impair the proliferation 
of oligodendrocytes and cause long-term dysfunction. Loss of myelin is a key aspect of 
the pathology of many diseases, such as multiple sclerosis, and therefore 
oligodendrocytes and their capacity for the production of myelin is at the center of much 
research [25]. 
 Unlike other resident cells of the CNS, microglia are not derived from 
neuroectoderm [26]. Microglia are the resident macrophage of the CNS; highly adapted 
to fit the needs of this unique environment. Microglia are derived from myeloid stem cell 
precursors and may be induced to express nearly all macrophage lineage markers [27], 
including CD45 (leukocyte common antigen). Similarly, mice lacking PU.1 (an essential 
transcription factor for myeloid cells) are incapable of producing microglia [28]. 
Microglia however, constitute a stable self-renewing population in the CNS, which is, 
only exceptionally replaced (if at all) by circulating immune cells in the blood [29] [30]. 
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The current model of the origin of microglia in human CNS is that the microglial stem-
cell migrants, emigrate from the extra-embryonic yolk sac as early as day 19 of fetal 
development [31], colonizing the CNS as early as 3 weeks gestational age [17], and that 
this settler population continues to mature and differentiate throughout gestational 
development within the CNS, having colonized the SC by week 9 and composing a well 
differentiated microglial population around week 35 [32]. 
 Microglia are highly adapted to live in the CNS; their morphology and physiology 
is therefor significantly different from other macrophage lineages. For instance, microglia 
rarely, if ever have a diameter of over 7.5μm [33] whereas macrophage have an average 
diameter of 13.8±2.3μm and have the capacity to ingest IgG opsonized beads of over 
20μm diameter [34]. In the relatively quiescent state, microglia are referred to as being 
“ramified,” named after their highly branched morphology. Upon activation in times of 
inflammation, microglia become more “amoeboid” in shape [33]. Although microglia are 
oftentimes demonized in scientific literature (being coined the “enemy within”) for the 
damage they can induce on the parenchyma of the CNS in times of inflammation [33], 
evidence suggests that microglia are most often expressing anti-inflammatory and 
neurotropic agents [35] and are pivotal in CNS homeostasis, recycling cell debris and 
clearing valuable realty [36]. 
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The Blood Brain Barrier and Central Nervous System Immune Privilege  
 
The blood brain barrier (BBB) is a multilayered filter that protects the CNS from 
toxins found circulating in the blood as well as virus and bacteria, which have managed 
to infiltrate the blood. The first layer of the BBB is the tight junctions found 
interconnecting the endothelial cells which line capillaries of the CNS. In most other 
areas of the body, endothelial cells are more permissive in their admission of chemicals 
into the interstitial space of organs, but in the CNS they are highly restrictive (this 
excludes the circumventricular organs of the CNS; sensory and excretory organs which 
require direct contact with the full array of chemicals found in the blood) [21]. 
The next obstacle of the BBB is the space itself filled with interstitial fluid, found 
on the basal aspect of the endothelial cells; a space referred to as the Virchow-Robin 
spaces (VRS). This space is a key component of the BBB, as it forms a barracks for 
compliment factors and antibodies and can accommodate B cells, T cells as well as 
monocytes/macrophages in the event that pathogens make it past the tight junctions of the 
endothelial cells. Immune cells are rarely allowed past this lumen, since the collateral 
damage that can result from their anti-pathogenic activities is oftentimes devastating in 
the CNS [37]. The VRS is also found lining the subarachnoid and the subpial space [38]. 
The VRS is usually indiscernible with magnetic resonance imaging (MRI) but becomes 
noticeable (dilated) in certain pathological situations (such as infection), as well as in the 
normal aging of the brain. 
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 The third and final layer of the BBB is the glia limitans, composed of the 
astrocytic end-feet sheathing the capillaries of the CNS and the basement membrane that 
they fabricate and organize.  It is the presence of the glia limitans that regularly block 
infiltration of B-cells, T-cells and monocytes/macrophages. This last obstacle of the BBB 
also blocks proteins such as complement and antibodies from entering the interstitial 
space of the CNS. The glia limitans is also necessary in the initiation of the formation of 
the tight junctions between endothelial cells during the development of the BBB [39]. 
 
Cerebral Spinal Fluid Properties and Dynamics  
 
CSF fills the ventricles and sinuses of the CNS and totally encapsulates the CNS 
(except where nerves and blood vessels enter and exit) by filling the subarachnoid space.  
The distinction between CSF and interstitial fluid of the CNS is maintained by the pia 
mater. The CSF serves several functions. First of all, CSF counteracts the crushing-effect 
that weight of the CNS would have on itself. The human brain weighs about 1400 grams 
however weighs only 25 grams when emerged in CSF due to the buoyant force that the 
displaced CSF exerts on the brain [40]. The CSF also provides cushioning against 
traumatic injury and [41] continuously rinses the CNS of toxins.  
The choroid plexus generates most of the CSF. This tissue lines the lateral and 3rd 
ventricles of the ventricular system of the CNS and is composed of highly modified 
ependymal cells.  CSF is reabsorbed primarily through the dural venous sinuses, by route 
of the arachnoid granulations and through the lymphatic channels stemming from where 
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the cranial and spinal nerves exit the CNS [42]. The total volume of CSF in the adult 
human is 150mL and is produced at a rate of about 500mL/day [41]. The total volume of 
CSF in mice is 0.04mL [43] and is produced at a rate of 0.475mL/day [44]. Following 
intrathecal (IT) (subarachnoid space) injection and/or increased CSF production, uptake 
of CSF will increase to meet the demand.  Following injection of radionuclides into the 
lumbar cistern of human patients, a 20% reduction of radioactivity in the following hour 
is normal [45]. When radioactive albumin is introduced the same way into mice, it is 
removed at a rate of about 1% /minute during the first hour following injection [46], 
correlating to the faster turnover rate of CSF in adult mice opposed to adult human.  
Delivery of IT injected fluids to specific regions of the CNS can be further 
specified by manipulation of the density of the injected fluid [47]. Dividing the density of 
the fluid by the density of CSF fluid determines a value referred to as the baricity of that 
fluid. Injection of a hyperbaric fluid into the lumbar region with a patient sitting in an 
upright position will cause the injected fluid to stay in the locality of the lumbar spine 
whereas injection of a hypobaric solution in a similar manner will deliver the injected 
drug to more cranial structures of the CNS. 
 
General Review of Wild Type Adeno-Associated Virus  
 
Subsequent to its discovery in the 1960s as an impurity in adenovirus stocks 
(from which the name derives), much has been learned about Adeno-Associated Virus 
(AAV) [48]. In its naturally occurring form, AAV is referred to as wild type AAV 
(wtAAV). AAV is part of the family Parvoviridae, which encompasses the smallest of all 
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known viruses. Parvoviruses are the only viruses with a linear, single stranded (ss) DNA 
genome that replicate in the nuclei of vertebrate and invertebrate cells [49]. Similar to the 
genome of other parvoviruses, AAV genome’s size is limited to about 5000 base pairs 
(BP). Initially, it was thought that for this reason, AAV biology would be easier to 
understand, but due to its short genome, AAV has a relatively large dependence on 
normal cell machinery (as well as proteins from helper virus), which complicates its 
research [48]. 
In the family Parvoviridae, there exist three genera of virus; AAV belongs to the 
genus Dependovirus. The dependovirus are known for their replicative defectiveness, in 
the absence of a helper virus (such as adenovirus or herpes virus). AAV’s dependence on 
helper-virus is evolutionarily a double edged sword; AAV cannot efficiently replicate and 
spread without co-infection, but on the other hand, AAV’s relative simplicity allows for it 
to be highly effective in infecting a large array of cell types from many different species 
of animal [48]. 
Though many serotypes of AAV exist, AAV2 serves as the prototype for the 
AAV [50]. The AAV2 genome is essentially composed of three “native” promoters (P5, 
P19 and P40; named for the map unit position) and two genes. At either end of the 
genome there is an identical palindromic sequence, which forms a self-complimentary T-
shaped structure referred to as an Inverted Terminal Repeat (ITR) [51]. The first of the 
two genes (the rep gene), codes for (up to) 4 non-structural proteins (Rep78, 68, 52 and 
40) that coordinate viral packaging (and host genome integration) by repressing and 
activating different host and AAV genes and by interacting with the AAV’s ITRs, to 
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shuttle AAV genome into viral particles. Both the ITRs and rep proteins are essential for 
DNA packaging and replication. The second of the two genes (Cap gene), codes for the 
three structural proteins (VP1, VP2 and VP3) that compose the capsids of the viral 
particle and a forth protein, assembly activating protein [52], which as the name implies, 
assembles the capsid proteins into intact capsids.   
AAV infection is different in the presence and absence of helper virus. In the 
absence of helper-virus, relatively little is known about the lifecycle of AAV because of a 
lack in research enthused by AAV’s defective nature. Without helper virus, AAV is 
capable of clathrin-coated vesicular uptake into the cytoplasm [53] and late-stage 
liposomal escape [54] followed by nuclear penetrance and site-specific integration into 
the human genome (chromosome 19) [55] but is incapable of replication and packaging 
[56]. In vivo, AAV particles are virtually non-existent in the absence of an active helper-
virus infection [57]. When AAV infection is coupled with adenovirus, the AAV 
essentially follows in the wake of the (more methodically aggressive) adenoviral 
infection route of entry (for example, early lysosomal escape). The presence of certain 
proteins encoded from helper-virus genome (for instance E1A, E4 and E1B in the case of 
adenovirus [58]) initiates a rapid and efficient replication of AAV genome through an 
interaction with host and AAV genes and proteins [59]. 
The activation of AAV replication by helper virus is so efficient that AAV 
replication interferes with adenovirus replication by directly competing with the 
adenoviral genome for the host’s replicative proteome. This fact, coupled with the 
observation that AAV is non-pathological [60] and that 80% of the human population test 
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seropositive against AAV antibodies (serotype 1, 2, 3 and 5) [61] suggests that AAV may 
actually form a symbiotic relationship with its host [57]. Furthering the hypothesis that 
AAV serves a protective effect for its host, it has been found that individuals infected 
with human papilloma virus (HPV) are less likely to develop cervical neoplasia when 
AAV is present [62] (14% of women with cervical cancer test seropositive for AAV 
antibodies, whereas 85% of healthy woman test seropositive [63]). 
 
Recombinant AAV  
 
Recombinant AAV (rAAV), a modified version of AAV designed specifically for 
introducing specific therapeutic transgenes was created in the 1980s [64] using wtAAV 
as a template, and has become a spearhead of gene therapy in the world today. rAAV 
design is brilliant;  essentially the AAV genome is spilt into separate cis and trans 
plasmids. The cis-plasmid contains AAV2 ITRs, an efficient promoter and a gene of 
interest (Rep and Cap genes are removed), whereas the trans-plasmid is composed of a 
promoter and the rep and cap genes (ITRs are removed). When the cis and trans plasmids 
(as well as an adenoviral helper plasmid) are “triple transfected” into HEK293 cells, the 
rep proteins from the trans-plasmid interact with the ITRs of the cis-plasmid, and 
incorporate the ITR-flanked cis-plasmids into AAV capsid “shells”, expressed from the 
trans-plasmid [65]. Once these rAAV particles are isolated from the culture, they can be 
used to deliver the gene of interest for therapeutic purposes. Because only the cis-plasmid 
is packaged (lacking both Rep and Cap genes), the rAAV is incapable of both host-
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genome integration and further replication. The rAAV, after entry into the nuclei of 
transduced cells, exists in the form of concatemers, separate from the host genome.  
Further advances in the design of rAAV have greatly increased transgene 
expression. DNA can only be “read” by host-cell transcriptional machinery if the proteins 
(such as polymerases) can meaningfully interact with the DNA, which must be double 
stranded (ds). DNA delivered by traditional rAAV is single stranded (ss). The rate-
limiting step for expression of genes delivered by rAAV is the “second strand synthesis” 
of the rAAV genome from ssDNA into dsDNA [66]. Self-complimentary AAV (scAAV) 
is designed so that a “mutant” ITR is introduced into the middle of the rAAV genome and 
the second half of the genome is complimentary to the first half. Therefore, after scAAV 
is expelled from the delivering AAV particle and introduced into the nucleus of the cell, 
it will immediately fold upon itself to form dsDNA and will be ready for transcription. 
An additional benefit is that scAAV genome is stabilized and has prolonged transgene 
expression [66]. The caveat is that only one half of the original amount of genome can be 
housed, 2.5 KB instead of the usual 5 KB.  
 
AAV for Therapeutic Use of CNS 
 
The domestication of AAV has allowed for rapid and accelerating increase in 
transduction efficiency over recent years, however several barriers continue to hinder its 
effectiveness. These barriers can generally be categorized into three classes, (1) host 
immunological response, (2) lack in efficiency of viral transduction and (3) non-
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specificity in targeting of desired cell type. In our study, we used different methods of 
injection to address all three of these issues in the murine CNS.  
There are many serotypes available for use, but in the goal of transducing the cells 
of the adult murine CNS, rAAV9 has emerged as the most efficient when introduced to 
the CNS via transthecal injection [67] and intraparenchymal injection [68] even when 
compared with AAV 2.5, a vector specifically and rationally designed for this purpose. 
AAV9 is also one of the most effective serotype in CNS transduction when introduced 
via intravascular injection in neonatal mice [69]. Evidence shows that AAV9 appears to 
be better at globally dispersing itself within the CNS, irrelevant as to how it was 
introduced. Also important in the supremacy of AAV9 for use in CNS transduction, 
comparing cross-reactivity of neutralizing antibodies against the various serotypes of 
AAV, AAV9 seems to be of a different clade from serotypes 1-8 [70]. This increases its 
potential use as a vector as it is more likely to bypass the adaptive immune system for 
most patients. 
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METHODS 
 
Expression Vector Design 
 
Two distinct vectors were designed for use in the two trials of our study. Both 
vectors contain rAAV2 ITRs. These two vectors differ in that scAAV.CB.PI.EGFP also 
contains mutant ITR (as it is a self complimentary form of AAV) and that they carry 
different transgenes (EGFP and Fluc) as depicted in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2: scAAV9.CB.PI.EGFP and ssAAV9.CB.PI.Fluc Construct Design 
Key; CB= Chicken-beta Actin Promoter; V (crooked line insert)=Intron; pA= polyadenylation 
signal; ITR= 5’ and 3’ (WT) and mutant inverted terminal repeats 
pA	  
Fluc	  
EGFP	  
CB	  
WT	  ITRs	  
5’	  ITR	  
Mutant
	  ITR	  
3’	  ITR	  
CB	  
pA	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AAV Vector Plasmid Construction  
 
In the attainment of desired DNA fragments, unwanted DNA was liberated from 
plasmid backbones (attained from Dr. Guangping Gao) by the application of restriction 
endonucleases. These DNA fragments were then separated from one another by agarose 
gel separation followed by DNA extraction with Qiagen Qiaquick Gel Extraction Kit. 
The isolated DNA fragments were then mixed with one another in the presence of T4 
Ligase.  
 
Transformation with DH5α™ Competent Cells and Plasmid Preparation 
   
Invitrogen Max Efficiency® DH5α™ competent cells, stored at -80°C, were 
thawed on wet ice for 10 minutes. 0.5 μL of AAV construct was mixed with 50 μL of 
competent cells in micro-centrifuge tube. Tubes were placed on wet ice for 30 minutes 
followed by a 45 second emersion in 42°C water bath. Tubes were then placed on ice for 
2 minutes. 400μL of SOC medium was added to each tube followed by a 1 hour 
incubation at 37°C on an orbital shaker. 20μL of cell solution was then added to agar 
plates containing ampicillin. These plates were incubated at 37°C overnight. A single 
colony was selected from the plate and used to inoculate 5mL of TB medium (containing 
ampicillin). Inoculated TB was then incubated at 37°C for 12 hours on an orbital shaker 
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(set at 250 revolutions/minute). The bacterial cells were then isolated by centrifugation 
and removal of supernatant.  
 The amplified plasmid was then harvested using the QIAGEN Qiaprep® Spin 
Miniprep Kit. Purity of DNA was measured using the Synergy™ HT Multi-Mode 
Microplate reader. A diagnostic restriction endonuclease digest was performed before 
sample was sent to Eurofins MWG Operon for DNA sequencing.  
 After sequence verification the transformed DH5α cells were amplified in TB 
medium (containing ampicillin) and plasmids were harvested using the CsCl2 
centrifugation. Before transfection, purity and restriction enzyme diagnostics were again 
conducted. 
   
 
rAAV9 Packaging by Triple Transfection, Purification and Titration 
 
Plasmids were then given to the Viral Vector Core of the Gene Therapy Center at 
UMASS Medical School for packaging, purification and titration. Packaging was 
accomplished by triple transfection in HEK293 cells. Purification was accomplished with 
the use of CsCl2 and ultracentrifugation. Subsequently, CsCl2 was removed using 
dialysis. Viral titer was then determined by quantification of intact viral capsid protein 
(VP1, VP2 and VP3) concentration via silver stain and subsequent agarose gel separation. 
Viral genome concentration was then quantified using qPCR. 
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Experiment 1: Optimization of rAAV9 Infusion Dosage 
  
  In optimizing transduction of cells within the CNS, dosage is of paramount 
importance. Optimized dosage of infused rAAV9 should ideally be as large as possible to 
maximize cellular transduction without exceeding an amount that unnecessarily exposes 
the patient to the risk of side effects. Side effects result as either a direct result that AAV 
particles have on the natural cell machinery of the host and also by their effect on 
initiating host immune response. Side effects can also present as a result of the transgene 
overexpression, especially when transgenes are used that code for proteins foreign to the 
cell’s natural proteome. Some transgenes code for proteins that are notorious for eliciting 
transgene toxicity, such as EGFP [71].  
Animal research was conducted in conformity with all federal and USDA 
guidelines, as well as an IACUC approved protocol. Prior to injection of animals, 
integrity of AAV vector was assessed by incubating at 37°C in an Alzet® Osmotic Pump 
for a 72 hour duration in PBS and measuring the relative efficiency that the cultured viral 
particles had in regards to transfection of HEK293 cells.  All mice in the study were wild 
type C57BL 6/J mice and received treatment at 6 weeks of age. Treatment consisted of 
scAAV9.CB.PI.EGFP via different methods of injection/infusion. 3 mice each received 
2E12 GC via tail vein injection, 3 mice received 1E+12 GC (high dose) via an Alzet® 
100μL osmotic pump (72 hour infusion duration) and a third set of 4 mice received a 
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dosage of 3E+11 GC (low dose) via the same pump design (100μL osmotic pump/ 72 
hour infusion duration). Another 2 mice served as a no-treatment control group.  
All mice were sacrificed at 9 weeks of age via transcardial perfusion with ice cold 
PBS, followed by 4% PFA and were stored in 4% PFA prior to further tissue processing. 
Pumps were removed post-mortem. Brain, spinal cord, liver, heart and gastrocnemius 
muscle were all extracted and were progressively dehydrated in graded solutions of 10%, 
20% and eventually 30% sucrose (1 to 2 days per solution). After dehydration, tissues 
were embedded in O.C.T. compound and were sectioned with a Thermoscientific Microm 
HM 550 cryostat. CNS tissues were sectioned 40μm thick and peripheral organs were 
sectioned 8 μm thick.  
Sections were stained with DAPI and immunofluorescence staining was 
performed with antiGFAP, antiEGFP and antiNeuN and their respective secondary 
antibodies. To verify EGFP expression, Avidin: Biotinylated enzyme Complex (ABC) 
staining was also performed. 
 
Experiment 2: Comparison of Two Different Intrathecal Pump Delivery Methods 
 
In Experiment 2 we utilized the two commercially available Alzet® Osmotic 
Pump designs (one delivering 100μL/72 hours and the other delivering 200μL/24 hours) 
which differ in their flow rate (as well as total volume delivery). All mice in experiment 
receiving injection/infusion of rAAV9 (n=19) underwent surgery at 6 weeks of age while 
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sedated with continuous administration of isoflurane. 7 mice received 8E+10 GC of 
rAAV9 (4 received scAAV9.CB.PI.EGFP and 3 received ssAAV9.CB.PI.Fluc) via an 
8μL intrathecal injection (duration=10 minutes), 6 mice received 1E+12 GC of rAAV9 (3 
received scAAV9.CB.PI.EGFP and 3 received ssAAV9.CB.PI.Fluc) via a 100μL 
intrathecal infusion (duration 72 hours), and 6 mice received 2E+12 GC of rAAV9 (3 
received scAAV9.CB.PI.EGFP and 3 received ssAAV9.CB.PI.EGFP) via a 200μL 
intrathecal infusion (duration 24 hours). 2 untreated mice served as a control group. A 
follow up procedure, in which pumps were removed from isoflurane-anaesthetized mice, 
was performed one day after the termination of pump duration (pumps of the 200μL 
group were removed after 2 days of implantation and those of the100μL pump group 
were removed after 4 days of implantation). 
An in vivo Fluc Assay was performed on isoflurane-anaesthetized 
ss.AAV9.CB.PI.Fluc injected mice, in which Fluc substrate (D-Luciferin) was introduced 
via intraperitoneal injection. Emitted luminescence was subsequently measured. 
All mice were sacrificed at 9 weeks of age. Tissue processing procedures of mice 
injected with sc.AAV9.CB.PI.EGFP were executed exactly as was accomplished in 
Experiment 1, except for in the case of the EGFP expression in which evaluation was 
conducted by means of direct EGFP expression. These tissues, after dehydration with 
graded concentrations of sucrose as was done in experiment one were placed under the 
fluorescent microscope for direct florescence of EGFP and subsequent imaging. 
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Mice injected with ss.AAV9.CB.PI.Fluc were sacrificed with administration of 
isoflurane followed by the immediate dissection and removal of tibialis anterior muscle, 
gastrocnemius muscle, heart, liver, brain and SC. Harvested tissues were immediately 
placed on a Styrofoam plate, floating in liquid nitrogen for rapid freezing.  Tissues were 
then set in 2 ml micro-centrifuge tubes and placed on dry ice. Following completion of 
dissection, tissues were stored in -80°C freezer. Each of the frozen organs were 
successively ground into individual homogenous organ mixtures using the Bel-Art/ 
Scienceware Liquid-Nitrogen-Cooled Mortar and Pestle and stored again in -80°C 
freezer.  These tissues were then used for post-mortem Fluc assay in which the tissues 
were solubilized in passive lysis buffer. Thermoscientific Pierce™ BCA Protein Assay 
Kit was used to measure total protein concentration and firefly luciferase assay was then 
performed using the Promega Fluc kit.  
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RESULTS 
 
In-Vitro Characterization of rAAV9 Vector and Capsid Stability 	  
The infusion of AAV into the IT space from the Alzet® osmotic pump is not 
instantaneous. In the group of mice receiving rAAV9 via the 100μL pump, a portion of 
the AAV particles remain within the plastic confines of the storage vessel of the sub-
dermally located pump for up to 72 hours. Due to the sub-dermal positioning, AAV 
incubation temperature is at body temperature (37°C). This raised our concern, regarding 
the stability of rAAV9 during this incubation period. Temperature is a major factor 
contributing to vector/virus instability during ex-vivo incubation. [72] 
 To confirm that the AAV’s integrity would not be excessively diminished, we 
performed a preliminary in-vitro analysis using silver stain for viral capsid proteins. We 
found that when incubated at 37°C, 22% of intact viral particles were lost after a 24 hour 
incubation and 38% were lost after a 72 hour incubation as shown in FIGURE 3.  
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                                                               4°C                        32°C 
                                                  
 
 
 
 
 
 
   
FIGURE 3: Silver Staining of scAAV.CB.PI.EGFP after Incubation 
 
Functionally, active particles of rAAV9 are lost by continuous and exponential 
decay, with a calculated half-life of approximately 104 hours (half-life= elapsed time x 
log 2/ log [beginning amount/ending amount]). The ejection of rAAV9 particles from the 
storage vessel of the pump into the IT space of treated mice is driven by the osmotic flow 
of interstitial fluid into the pump, which is calibrated by the pump’s design to be 
relatively constant over the duration of the infusion period. This rate of infusion is 
considerably higher than the rate of AAV loss by thermal degradation. Consequently, 
rAAV9 particle degradation in the pump does not significantly contribute to the loss of 
transfection in our study.  
6 h 48 h 72 h 24 h 72 h 
Semi-quantification (%): 100 92 78 71 62 
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We also performed an analysis to directly quantify the diminishment of the 
incubated rAAV9 infectalbiity to verify that incubation temperature did not contribute to 
additional loss of transducibility by other mechanistic means, independent of rAAV9 
particle cohesion. To do this, we co-infected HEK293 cells with scAAV9.CB.PI.EGFP 
and Ad Helper after various incubation times at 37°C and measured EGFP florescence 
after various intervals leading up to a 72 hour. As a control we compared this florescence 
with that from a HEK293 co-infection with rAAV9 that used immediately after thawing 
(from -80°C freezer) and with scAAV9 that had been incubated at 4°C for 72 hours. 
Results are shown in FIGURE 4 and are quantified in FIGURE 5. 
 
 
 
                              
  
            
 
 
 
   6-Hour Incubation    24-Hour Incubation   42-Hour Incubation   72-Hour Incubation 
  
 
FIGURE 4: Co-infection of HEK293 Cells with scAAV9.CB.PI.EGFP after 
Incubation with an Adenovirus Helper  
Directly after thawing 
 MOI 
AAV 10E5 
Ad 50 
Pump Incubated at 37°C 
72-Hour Incubation 
Pump Incubated at 4°C 
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                                                100% 95%     106% 87%  79%  69%     69%(p=0.01) 
 
 
 
                                                0 hrs  72hrs     6hrs  24hrs 48hrs 72hrs 
 
 
 
 
FIGURE 5: Quantification of Infectability after Incubation 
 
 
The quantification of the infectability of the incubated virus showed evidence that 
the viral performance is even less effected than would be initially assumed via analysis of 
the rAAV9 particle degradation itself.  For the purposes of this study, in-vitro assays 
reassured us that our results would not be confounded by the loss of rAAV9 infectability 
due to time spent in the pre-injected pump storage devices after surgical implantation. 
 
 
 	  	  
4°C Pump 37°C Pump 
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Experiment 1: Optimization of rAAV9 Infusion Dosage 
 
Coronal sections of brain and SC revealed patterns of EGFP expression that 
correlate to method of delivery as well as to vector titration. (FIGURE 6) CNS sections 
taken from “No Treatment” control mice, show no EGFP expression, however these 
sections do show a faint background florescence resulting from the residual PFA used in 
the preservation of these tissues. CNS from the tail-vein injected mice show a 
transduction-pattern throughout the CNS (primarily in the hindbrain structures and the 
SC) which appears to co-localize predominately with astrocytes (FIGURE 6).   
           
FIGURE 6: Anti-EGFP Florescence in Various CNS Regions from Experiment 1 
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Sections from both pump-groups express pronounced fluorescence with sections of the 
SC in the lumbar spine experiencing the most dramatic transduction. This pattern of 
transduction can be explained by the placement of the catheter’s tip and CSF fluid 
dynamics in the SC. These sections also reveal, particularly in the high-dose rAAV9 
pump group, additional occurrence of transduction in the cervical, thoracic and lumbar 
locals farther up in the CNS (notably the brainstem and cerebellum).  
 Lumbar sections from all of the mice in Experiment 1 receiving infusion via 
pump cannula insertion revealed the presence of a hyperplastic mass on the ipsilateral 
side of the SC, with respect to pump-catheter placement.  The hyperplastic mass itself 
stems from a region of SC showing extraordinary EGFP expression, however shows poor 
EGFP expression itself. Due to this fact, it can be determined that the mass is unlikely to 
have been present before the time of injection, because it is improbable that the tissue 
within the mass is altogether “immune” to rAAV9 transduction. This therefore indicates, 
that the mass was not present prior to transfection/surgical implantation and is likely to 
have resulted from either the massive transduction or as a result of the surgery itself. This 
mass could either have resulted from cellular disruptions in DNA self-regulation, caused 
by the massive influx of excessive rAAV9 into the nuclei of transduced cells or could 
have developed as a form of astrogliosis (CNS scarring), subsequent not to transduction 
but to direct physical damage to the SC during catheter implantation and/or continual 
abrasion of the catheter against the wall of the SC during the 3 week period of catheter 
implantation. Supporting the second hypothesis, mice of the pump groups in Experiment 
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2, which had the pump catheters removed on the day following the end of the pump 
infusion’s duration, lacked such growths in all regions of the SC. Further IF staining and 
analysis (not yet conducted) will shed more light on the origins of this mass. 
 
FIGURE 7: AntiEGFP/AntiNeuN Colocalizion in Ventral Horn from Experiment 1 
 
 The transduction resulting from IT pump groups co-localizes with both astrocytes 
and neurons and is most predominant in subthecal regions, correlating with the 
hemisphere in which the mouth of the pump’s catheter was placed. This co-localization is 
well exemplified in the region of the ventral horn as is depicted in FIGURE 7. The 
EGFP 
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ventral horn is an area of large clinical concern because of the diseases that affect motor 
neurons. 
  
 
 
FIGURE 8: ABC Stain for EGFP Shows Increased Transduction of Neuronal 
Bodies in Region of the Ventral Horn in the 200µL Pump Infused Mice 
Key: Arrows point to neurons 
 
Avidin-biotin complex (ABC) staining was used to verify the location and degree 
of EGFP transgene expression within the region of the ventral horn as shown in FIGURE 
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8. This staining was performed because of the clinical relevance of this region and the 
prior results suggesting excellent transduction of AAV9 in these regions. 
 
Experiment 2: Comparison of Two Different Intrathecal Pump Delivery Methods 
 
Expression of EGFP in the cervical, thoracic and lumbar regions was most 
pronounced in the 200μL pump group. (FIGURE 9) Results in this regard, were very 
similar to those from experiment 1, areas with close proximity to the mouth of the 
cannula being transduced to a greater degree for most of the sections observed, however 
when a lower intensity setting was used to observe the extent of EGFP expression in the 
most impressively transduced lumbar sections it was found that greatest florescence was 
observed in the center of the section, correlating with the tissue encircling the central 
canal.  (FIGURE 9) 
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FIGURE 9: Strong Transduction in Spinal Cord After 200ul/1 day Infusion 
 
SC sections were stained with antiGFAP to assess if there was a change in the 
absolute number and/or size of SC astrocytes of transfused mice (FIGURE 10). No 
significant difference was noted in the florescence of the GFAP marker, indicating that 
astrocytosis (activation, enlargement and proliferation of astrocytes as a component of 
inflammation and for generating CNS scar tissue) was not present at the time of animal 
sacrifice (3 weeks post surgery). This lack of astrocytosis, together with the lack of 
hyperplasia in the entire set of pump treated mice of experiment 2 contrasts with the 
hyperplasia in Experiment 1, which affected literally every pump treated animal to some 
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FIGURE 10: Lack of Astrocytosis After Pump Infusion 
 
 
degree. Hyperplasia found in Experiment 1 was most likely due to the fact that the 
cannulas (in Experiment 1 only) were left inserted into the murine vertebral column for 
the entire three-week post-operative period before animal sacrifice. SC abrasion against 
the wall of the cannula may have caused this hyperplasia. 
ABC Staining for EGFP verifies that the SC of the 200μL pump infused mice 
most dramatically expresses EGFP (FIGURE 11) when compared with other forms of 
delivery including the results gathered from the tail-vein injected mice in Experiment 1.  
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FIGURE 11: ABC-Peroxidase-DAB Staining 
 
The analysis of the direct EGFP florescence in the wholly removed brain and SC 
further illustrates the unmistakably increased expression of EGFP in the SC region 
correlating to the region of catheter placement as well as to regions of SC caudal to its 
location. (FIGURE 12) Peripheral organs also expressed EGFP florescence. (FIGURE 
13)  
In vivo imaging of Fluc luminescence after intraperitoneal injection of D-luciferin 
also demonstrates that the 200μL group most appreciably expresses the delivered Fluc 
transgene. (FIGURE 14) 
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FIGURE 12: Flourescence Imaging after Infusion with scAAV9.CB.PI.EGFP 
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 FIGURE 13: Imaging of Wholly Removed Peripheral Organs after Infusion with 
scAAV9.CB.PI.EGFP 
 
 
 
 
 
 
 
 
 
	  37	  	  
 
 
 
FIGURE 14: In Vivo Imaging of Fluc Luminescence Following Intraperitoneal 
Injection of D-Luciferin 
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DISCUSSION 
  
  
AAV has been suggested as a plausible cure for many genetic disorders of the 
CNS and though delivery of AAV to this uniquely protected organ-system requires 
further research, significant progress has been made in a relatively short time. The CNS is 
the perfect candidate for AAV delivered gene therapy because of the highly regulated and 
relatively quiescent turnover rate of the majority of its cell populations, and the relatively 
antibody-free nature of this body region. These populations, however, are closely guarded 
from transfection of AAV by the various obstacles presented by the BBB. In 2009, 
research conducted by Foust et. al. showed that temporal-vein delivery of AAV9 in one-
day-old mice, successfully bypassed the BBB, appreciably transducing  the neuronal and 
glial cells of the CNS [69]. Though this study marked a huge success in AAV mediated 
gene therapy of the CNS, its application is limited to an extremely young age (day-one 
old mice), in which the BBB is not completely developed. This method appears to be 
ineffective in transducing neurons; predominantly transducing the astrocytes of the CNS 
once this window of opportunity is missed.  
 Injection of AAV directly into the IT space of the CNS proves to be an effective 
method of attaining global and dramatic CNS transduction in adult populations of species 
in which it has been studied. The importance of which is illustrated by the fact that those 
treated have fully intact BBBs. IT injection of adult rodents has shown successful 
transfection of neurons and glial cells, and has moreover provided the literal cure for the 
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mice-model form of mucopolysaccharidosis type 1 [73]. The importance of mice-model 
progress in IT delivery of AAV has been additionally substantiated by the finding that the 
correlation between transducibility (of neurons and glial cells) and rAAV9-dose in mice 
can be readily translated into application in non-human primates [67]. Our research is 
meant to optimize the tranducibility of subarachnoid-space (SAS) introduced rAAV9 and 
to better understand the underlying mechanisms by which transfection can be modified.  
Furthermore, we have confirmed IT introduction of rAAV9 as a potent transducer of 
neurons/glial cells in adult mice.  
 Our first experiment shows that the highest dose of rAAV9 (1E+12 GC) 
correlates with the most global and pronounced transduction of mouse CNS.  To more 
wholly confirm that this dose does not induce complications due to CNS scarring and/or 
inflammation, staining of these sections with GFAP (as a marker of astrocytosis) and 
IBA1 (as a marker of microgliosis) is underway. If we find that there are issues with 
either of these parameters, further modifications to the rAAV9 design can be made to 
avoid detection from both the innate and acquired immune system. Furthermore, stains 
for the oligodendrocytes (anti-oligodendrocyte specific protein), microglia (antiIBA1) 
and motor neurons (antiCHAT or antiSMI-32) will further illustrate the effects of 
delivery dosage and method on vector tropism in the CNS. 
 In our second experiment, we further studied CNS transduction efficiency by 
comparing two different pump delivery methods. This experiment gave us valuable 
insight into the safety and value of utilizing the larger volume (and larger dosage) pump. 
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We conclude that the larger 200μL (2E+12 GC dose) pump group was the most 
successful in transduction efficiency and coverage of CNS. It is most likely that the larger 
pump size correlated with a greater transduction efficiency and coverage because it 
allowed for a greater overall dosage to be delivered.  
In the delivery of rAAV9 by direct injection or infusion into the subarachnoid 
space, flow-rate of volume and flow-rate of rAAV9 particle are important parameters to 
optimize. These “flow-rates” can be quite independent of one another if overall dosages 
of the different “treatment” groups are not constant, as is the case in experiment 2 (See 
Table 1). In experiment 2, our 200μL group receives the highest overall dosage of 
rAAV9 (2E+12 GC) and the highest rate in which the dosage was received (1.4E+9 
GC/min). Our 100μL pump group receives the lowest rate of rAAV9 particle delivery 
(2.3E+8 GC/min), but the second highest overall dose (1E+12 GC). 
Rate of volume flow into the IT space should not exceed a volume that can 
structurally damage CNS structures and/or impinge the natural circulation of CSF flow, 
however adjusting flow-rate of both volume and viral particle within a range that 
minimizes complication may effect the extent and spread of transduction within the CNS 
by the potential for generating an artificial “bulk flow” within and throughout the various 
CSF compartments of the sub arachnoid space (SAS), driven by the pressure difference 
generated by the infused “bolus.”  
Modification of flow-rate may also affect the degree to which the peripheral 
organs are transduced. CSF of the SC leaves the IT space via lymphatic drainage. The 
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lymphatic fluid, after passing through lymph nodes is dumped into the vena cava. Once in 
the vena cava the rAAV quickly flows through the right atrium, right ventricle, then the 
pulmonary loop and back to the right side of the heart before distribution throughout the 
rest of the periphery. Changing the pump flow rate may effectively maximize the amount 
of the vector that stays within the CNS. 
Repeating our second experiment with a constant dosage in all “treatment” groups 
will give us clear evidence as to the effects, which rAAV9 particle and volume rate have 
on transduction efficiency and dispersion (See Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  42	  	  
 8μL/10 min 100μL/4320 min 
(72 hours) 
200μL/ 1440min 
(24 hours) 
Dosage 1E+10 GC3 1E+12 GC2 2E+12 GC1 
Volume/min 0.8μL/min1 0.023μL/min 0.14μL/min 
Dosage/min 1E+9 GG/min2 2.3E+8/min3 1.4E+9 GC/min1 
Table 1: Relevant Parameters of Experiment 2 
key; 1= highest relative value of parameter(dosage, volume flow or dosage flow) 2= second 
highest relative value of parameter and 3=3rd lowest relative value of parameter 
 
 
 8μL/10 min 100μL/4320 min 
(72 hours) 
200μL/ 1440min 
(24 hours) 
Dosage X0 GC X0 GC X0 GC 
Flow=Volume/min 0.8μL/min1 0.023μL/min3 0.14μL/min2 
Dosage/min X GC/10min1 X GC/4320min3 X GC/1440min2 
Table 2: Modified Parameters for the Further Analysis of Dosage Rate 
 
key; X0= consistent GC amount 1= highest relative value of parameter(volume flow and 
dosage flow) 2= second highest relative value of parameter and 3=3rd lowest relative value of 
parameter 
 
Note: By keeping dosage the same between groups, relative amounts of volume and GC flow 
correlate with one another  
 
 Though the IT injection/ infusion that we performed in our first two experiments 
are both located in the region of the thoracic SC, we are currently in the process of 
comparing the relative transduction that results from IT infusion in other regions of the 
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CNS. We are particularly interested in evaluating the implantation of a pump cannula into 
the lateral ventricles of mice (ICV infusion), as this region (containing the majority of 
choroid plexus) generates most of the CSF and drives the “bulk flow” within the CSF 
space. Though the cisterna magna has proven to be an effective (and logical) point of 
injection in non-human primates [67], we consider this location for IT injection/infusion 
in mice to be unacceptably dangerous, due to the limited space available in the magnum 
foramen for syringe injection and/or catheterization. 
After the effects that parameter modification has on CNS transfection (intensity 
and spread) as well as cell tropism are better understood, we may effectually take a step 
back and modify transgene promoters to better treat diseases rationally. In the case of 
disease treatment, more is not equivalent to better. Replacing the CB promoter, used in 
our study and notorious for its extremely diligent initiation of transgene transcription, 
with a more cautious promoter may be more appropriate for real-life applications. Use of 
tissue-specific promoters in the CNS (possibly MeCP2 promoter [74]) or the use of 
promoters specific for neurons, astrocytes, oligodendrocytes etc. may also be an eventual 
aspect of research, necessary for optimal transgene expression in CNS.  
 Overall, our results have proved that the use of pump infusion of rAAV9 into the 
IT space transduces neurons (as well as other cells in the CNS) of adult mice better than 
any other method commonly used to date. This finding is critical to the furthering of gene 
therapy of the CNS, especially in regards to therapy targeted for humans, in which larger 
vector quantities are required and procedural safety is paramount. Some day, pumps 
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placed in the IT space of humans may cure patients suffering from the vast array of CNS 
illnesses that are currently debilitating and/or fatal. 
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